Arcus Biosciences’ August 5 call looks routine, but its biggest pipeline test is approaching
Arcus Biosciences will report Q2 results on August 5 as investors assess casdatifan progress, pipeline execution and its cash runway.
Pharma & Biotech
Pharma & Biotech
What Arcus Biosciences’ casdatifan data reveal about durability limits in late-line renal cell carcinoma
Arcus Biosciences’ casdatifan data challenge assumptions about HIF-2α inhibition in kidney cancer. Explore what changes next and what risks remain.
Pharma & Biotech
What Arcus Biosciences’ STAR-221 failure reveals about TIGIT fatigue in immunotherapy
Arcus Biosciences, Inc. has terminated its global Phase 3 STAR-221 study evaluating domvanalimab, an investigational anti-TIGIT antibody, in combination with zimberelimab and chemotherapy for advanced upper gastrointestinal cancers. The discontinuation, announced in partnership with Gilead Sciences, Inc., followed a pre-specified interim overall survival analysis that found no benefit compared to the nivolumab-based control arm. Arcus